Christopher J LaFargue
Overview
Explore the profile of Christopher J LaFargue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nguyen M, LaFargue C, Pua T, Tedjarati S
Case Rep Obstet Gynecol
. 2013 May;
2013:807205.
PMID: 23710391
Most grade 1 endometrioid endometrial cancers are confined to the uterus at the time of diagnosis and confer a good prognosis. Rarely will a grade 1 endometrioid endometrial carcinoma present...
12.
Rickman D, Chen Y, Banerjee S, Pan Y, Yu J, Vuong T, et al.
Neoplasia
. 2010 Dec;
12(12):1031-40.
PMID: 21170267
To elucidate the role of ETS gene fusions in castration-resistant prostate cancer (CRPC), we characterized the transcriptome of 54 CRPC tumor samples from men with locally advanced or metastatic disease....
13.
Svensson M, LaFargue C, MacDonald T, Pflueger D, Kitabayashi N, Santa-Cruz A, et al.
Lab Invest
. 2010 Oct;
91(3):404-12.
PMID: 20975660
Prostate cancer is a clinically heterogeneous and multifocal disease. More than 80% of patients with prostate cancer harbor multiple geographically discrete cancer foci at the time of diagnosis. Emerging data...
14.
Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al.
Nat Med
. 2010 Jun;
16(7):793-8.
PMID: 20526349
Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene...
15.
Esgueva R, Perner S, LaFargue C, Scheble V, Stephan C, Lein M, et al.
Mod Pathol
. 2010 Feb;
23(4):539-46.
PMID: 20118910
The majority of prostate cancers harbor recurrent gene fusions between the hormone-regulated TMPRSS2 and members of the ETS family of transcription factors, most commonly ERG. Prostate cancer with ERG rearrangements...
16.
Bass A, Watanabe H, Mermel C, Yu S, Perner S, Verhaak R, et al.
Nat Genet
. 2009 Oct;
41(11):1238-42.
PMID: 19801978
Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development. Here we show that a...
17.
Wagner P, Perner S, Rickman D, LaFargue C, Kitabayashi N, Johnstone S, et al.
Am J Clin Pathol
. 2009 Sep;
132(4):500-5.
PMID: 19762526
Recent advances in the characterization of the lung cancer genome have suggested that KRAS may frequently be amplified, although little is known regarding the significance of this finding. This is...
18.
Ramos A, Dutt A, Mermel C, Perner S, Cho J, LaFargue C, et al.
Cancer Biol Ther
. 2009 Sep;
8(21):2042-50.
PMID: 19755855
In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer...
19.
Pflueger D, Rickman D, Sboner A, Perner S, LaFargue C, Svensson M, et al.
Neoplasia
. 2009 Aug;
11(8):804-11.
PMID: 19649210
A step toward the molecular classification of prostate cancer was the discovery of recurrent erythroblast transformation-specific rearrangements, most commonly fusing the androgen-regulated TMPRSS2 promoter to ERG. The TMPRSS2-ERG fusion is...
20.
Di Vizio D, Kim J, Hager M, Morello M, Yang W, LaFargue C, et al.
Cancer Res
. 2009 Jun;
69(13):5601-9.
PMID: 19549916
Oncosomes have recently been described as membrane-derived microvesicles secreted by cancer cells, which transfer oncogenic signals and protein complexes across cell boundaries. Here, we show the rapid formation and secretion...